Tilmann Bochtler

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

Stefan Schönland, Ute Hegenbart, Tilmann Bochtler et al. · Blood · 2011 · 246 citations · Full text

Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens

Tilmann Bochtler, Ute Hegenbart, Christina Kunz et al. · Journal of Clinical Oncology · 2015 · 224 citations · Full text

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Krämer, Tilmann Bochtler, Chantal Pauli et al. · Annals of Oncology · 2022 · 173 citations · Full text

Esophageal Cancer, Unknown Primary, Medicine +6

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Anna Brown, Peer Arts, Catherine Carmichael et al. · Blood Advances · 2020 · 150 citations · Full text

Allelic Variant, Developmental Biology, Somatic Mutations +15